跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
喜开悦 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Risankizumab Injection (Subcutaneous Injection)
Approved
生物制品
Risankizumab Injection (Subcutaneous Injection)
艾伯维公司
🇨🇳 National Medical Products Administration
Approval Date
Mar 4, 2025
Approval ID
8jXiO6Fpsb6
Company
艾伯维公司
Type
生物制品
Approval Details
Approval Id
8jXiO6Fpsb6
Approval Number
国药准字SJ20250008
Generic Name
利生奇珠单抗注射液(皮下注射)
Generic Name En
Risankizumab Injection (Subcutaneous Injection)
Trade Name
喜开悦
Drug Type
生物制品
Dosage Form
注射剂
Strength
360 mg（2.4 mL）/支
Reg Date
2025-03-04
Expired Date
2030-03-03
Company Name
艾伯维公司
Production Company Name
PATHEON ITALIA SPA
Company Detail Path
/organization/abbvie-cdr-cad-hedged
Production Company Detail Path
/organization/patheon-italia-spa
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Mar 4, 2025
Approval ID
8jXiO6Fpsb6
Type
生物制品
Back to NMPA Approvals
